JAZZ all Jazzed Up on AGN Rumor

Citing 3 industry bankers, dealReporter is saying that If Allergan

were looking for a defensive deal, Jazz Pharmaceuticals

would likely be most viable target. Shares of JAZZ, which have been the subject of much speculation lately, are getting a big lift on the news, trading higher by nearly 7 percent at 168. AGN is also higher by 0.78 percent at 166.80.